Here UK lead negotiator in trade talks with US says US patent issues could be problematic for “NHS access to generic drugs (ie cheaper drugs)”. Negotiator says “it will be a key consideration going forward”. Which plainly means negotiator is anxious about this. It does not... 
not mean UK will roll over and allow patent extensions that would push up price of drugs for NHS. Minister rings me to say that Tory manifesto explicitly rules out a trade agreement with US that would lead to increase in price of drugs for NHS. I ask minister if...
that pledge also means Johnson would reject any increase in patent length. Minister insists it does. So we are once again back to the issue of trust.
